The Entrepreneurs Series at the Mass General Research Institute is an educational program of talks where our most entrepreneurial researchers to share their expertise and experience in moving scientific discoveries along the translational pathway to market and patient care.

The series is an intellectual community for scientists at Mass General to learn from various examples of translation or startup company success and failure, share best practices, and get relevant mentorship and guidance.

The series is produced collaboratively by ECOR and the Office of the Scientific Director and in close collaboration with Mass Genera Brigham Innovation. This series is co-directed by Gabriela Apiou, PhD, and David Milan, MD

These events are open to all Mass General employees only. Questions or feedback? please email


Date: February 12, 2020 
Simches Building, Room 3.110, Massachusetts General Hospital
Time: All presentations are on Wednesdays from 4:30 pm – 6:00 pm

Orhan Muratoglu, PhD

Orhun Muratoglu, PhD

Professor, Orthopedic Surgery 
"Commercialization Journey of a Materials Technology to Eliminate Peri-Prosthetic Osteolysis, a Silent Disease Caused by Total Joint Arthroplasty"


The widespread adaption of highly crosslinked polyethylene as the acetabular liner and tibial insert used in total hip and knee arthroplasty, respectively, has substantially reduced the revision rate. The most recent estimates suggest that this technology has reduced the cost of total joint arthroplasty by over two billion dollars annually, in the US alone. We developed the first generation of this technology at Mass General in mid 1990s and translated it to clinical use shortly thereafter. The second generation technology came about after we realized that precursors of cholesterol can compromise long-term mechanical properties in vivo, which we addressed by vitamin-E stabilization of the material. The first human use of vitamin-E stabilized highly crosslinked polyethylene was in late-2000s. To date, over eight million patients have been treated using either of these technologies; and annually well over 1.5 million patients are treated using highly crosslinked polyethylenes.

Translation of these technologies required substantial preclinical data to support claims that the implants would have excellent long-term performance, well beyond 10-15 years – a common requirement for orthopedic implants. In addition to many preclinical testing, we designed hip and knee simulators to subject the implants to over 20 years of accelerated use. These data convinced two strategic partners to bring the technologies to clinical use under a co-exclusive license. We assisted our licensees in the regulatory clearances of their devices in many territories around the world. We also initiated the multi-center post-market surveillance studies to assess the long-term outcomes. Currently our clinical data with the first generation is at 20 years and the second generation is approaching 10 years, both with excellent results.

Past Talks
  • May 22, 2019 — From Bench to Bedside: Novel Diagnostic & Treatment for Acute Kidney Injury

    Sylvie Breton, PhD
    Investigator, Program in Membrane Biology/Center for Systems Biology, Massachusetts General Hospital
    Richard Moerschner Endowed MGH Research Institute Chair in Men’s Health
    Charles and Ann Sanders MGH Research Scholar
    Professor of Medicine, Harvard Medical School

  • January 23, 2019 — Advanced Drug Delivery Systems: The Journey from "Smart Infusion Pumps" to Closed Loop Control of Human Physiology in Anesthesia and Critical Care
    Nat Sims, MD, Physician Investigator, Department of Anesthesia, Critical Care and Pain Medicine; Assistant Professor of Anesthesia, Harvard Medical School
    Research scientist and medical device inventor
  • November 28,2018 — Venture Creation: A Case Study
    Jean-François Formela, MD, Partner, Atlas Venture
    Core Member, Research Institute Advisory Council Strategic Alliances Committee
  • September 26, 2018 - Internal Innovation to Bridge the Gap Between Academia and Commercialization -
    Mehmet Toner, MD, Helen Andrus Benedict Professor, HMS; Director of Research, Shriners Hospitals for Children; Director, BioMEMS Resource Center, Mass General, and Ravi Kapur, PhD, CEO, MicroMedicine Inc.; Entrepreneur-in-residence, Mass General Innovation Team Leader, Center for Circulating Tumor Cells, Mass General
  • June 20, 2018 - Intravascular Optical Coherence Tomography: A Translational Story
    Guillermo “Gary” J. Tearney, MD, PhD, Remondi Family Endowed MGH Research Institute Chair; Mike and Sue Hazard Family MGH Research Scholar; Professor of Pathology, Harvard Medical School
  • May 23, 2018 - Science for the People
    R. Rox Anderson, MD, Director, Wellman Center for Photomedicine